Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in moderate to severe hidradenitis suppurativa (16-week and 1-year efficacy and safety)
2018-002062-39Phase 3Unknown
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (3 arms), sponsored by Novartis. Primary endpoint: HiSCR response at Week 16. Status: unknown.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2018-002062-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002062-39.